JP2006507302A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006507302A5 JP2006507302A5 JP2004550143A JP2004550143A JP2006507302A5 JP 2006507302 A5 JP2006507302 A5 JP 2006507302A5 JP 2004550143 A JP2004550143 A JP 2004550143A JP 2004550143 A JP2004550143 A JP 2004550143A JP 2006507302 A5 JP2006507302 A5 JP 2006507302A5
- Authority
- JP
- Japan
- Prior art keywords
- amino
- pyrimidin
- compound
- carbonitrile
- thiazole
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- QSBMSTSCSFSHFR-UHFFFAOYSA-N 5-phenyl-n-[6-(piperidin-4-ylmethoxy)pyrimidin-4-yl]-1,3-thiazol-2-amine Chemical compound C1CNCCC1COC(N=CN=1)=CC=1NC(S1)=NC=C1C1=CC=CC=C1 QSBMSTSCSFSHFR-UHFFFAOYSA-N 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims 38
- 238000000034 method Methods 0.000 claims 36
- 206010028980 Neoplasm Diseases 0.000 claims 16
- 201000011510 cancer Diseases 0.000 claims 15
- 150000003839 salts Chemical class 0.000 claims 15
- 125000000623 heterocyclic group Chemical group 0.000 claims 14
- 125000003118 aryl group Chemical group 0.000 claims 12
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 11
- 125000001424 substituent group Chemical group 0.000 claims 11
- 229910052736 halogen Inorganic materials 0.000 claims 9
- 150000002367 halogens Chemical class 0.000 claims 9
- 239000003607 modifier Substances 0.000 claims 9
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims 8
- 241000124008 Mammalia Species 0.000 claims 8
- 125000000304 alkynyl group Chemical group 0.000 claims 6
- -1 2-morpholin-4-ylethyl Chemical group 0.000 claims 5
- 125000000217 alkyl group Chemical group 0.000 claims 5
- 239000000203 mixture Substances 0.000 claims 5
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 4
- 125000006663 (C1-C6) perfluoroalkyl group Chemical group 0.000 claims 4
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 4
- 229940121369 angiogenesis inhibitor Drugs 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 239000003112 inhibitor Substances 0.000 claims 4
- DNUTZBZXLPWRJG-UHFFFAOYSA-M piperidine-1-carboxylate Chemical compound [O-]C(=O)N1CCCCC1 DNUTZBZXLPWRJG-UHFFFAOYSA-M 0.000 claims 4
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 claims 4
- 125000006664 (C1-C3) perfluoroalkyl group Chemical group 0.000 claims 3
- LMCLAVRZNUMBHA-UHFFFAOYSA-N 2-[(2-methyl-6-piperidin-4-yloxypyrimidin-4-yl)amino]-1,3-thiazole-5-carbonitrile Chemical compound C=1C(OC2CCNCC2)=NC(C)=NC=1NC1=NC=C(C#N)S1 LMCLAVRZNUMBHA-UHFFFAOYSA-N 0.000 claims 3
- 102100032187 Androgen receptor Human genes 0.000 claims 3
- 125000006374 C2-C10 alkenyl group Chemical group 0.000 claims 3
- 229940122440 HIV protease inhibitor Drugs 0.000 claims 3
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims 3
- 229940123468 Transferase inhibitor Drugs 0.000 claims 3
- 125000003342 alkenyl group Chemical group 0.000 claims 3
- 108010080146 androgen receptors Proteins 0.000 claims 3
- 230000001028 anti-proliverative effect Effects 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 239000002254 cytotoxic agent Substances 0.000 claims 3
- 229940127089 cytotoxic agent Drugs 0.000 claims 3
- 231100000599 cytotoxic agent Toxicity 0.000 claims 3
- 239000003937 drug carrier Substances 0.000 claims 3
- 102000015694 estrogen receptors Human genes 0.000 claims 3
- 108010038795 estrogen receptors Proteins 0.000 claims 3
- 239000003102 growth factor Substances 0.000 claims 3
- 239000004030 hiv protease inhibitor Substances 0.000 claims 3
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- 102000027483 retinoid hormone receptors Human genes 0.000 claims 3
- 108091008679 retinoid hormone receptors Proteins 0.000 claims 3
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 claims 3
- 229910052717 sulfur Inorganic materials 0.000 claims 3
- 239000003558 transferase inhibitor Substances 0.000 claims 3
- QWTMSTGFUNYRJX-UHFFFAOYSA-N 2-[(6-piperidin-4-yloxy-2-propan-2-ylpyrimidin-4-yl)amino]-1,3-thiazole-5-carbonitrile Chemical compound C=1C(OC2CCNCC2)=NC(C(C)C)=NC=1NC1=NC=C(C#N)S1 QWTMSTGFUNYRJX-UHFFFAOYSA-N 0.000 claims 2
- PQKRBHFNUGEZEQ-UHFFFAOYSA-N 2-[[2-methyl-6-(morpholin-2-ylmethoxy)pyrimidin-4-yl]amino]-1,3-thiazole-5-carbonitrile Chemical compound C=1C(OCC2OCCNC2)=NC(C)=NC=1NC1=NC=C(C#N)S1 PQKRBHFNUGEZEQ-UHFFFAOYSA-N 0.000 claims 2
- YKOCOBQSAHSNNH-UHFFFAOYSA-N 2-[[2-methyl-6-(oxolan-3-ylamino)pyrimidin-4-yl]amino]-1,3-thiazole-5-carbonitrile Chemical compound C=1C(NC=2SC(=CN=2)C#N)=NC(C)=NC=1NC1CCOC1 YKOCOBQSAHSNNH-UHFFFAOYSA-N 0.000 claims 2
- KRKUIWZXGWIIKJ-UHFFFAOYSA-N 2-[[2-methyl-6-(piperidin-4-ylmethoxy)pyrimidin-4-yl]amino]-1,3-thiazole-5-carbonitrile Chemical compound C=1C(OCC2CCNCC2)=NC(C)=NC=1NC1=NC=C(C#N)S1 KRKUIWZXGWIIKJ-UHFFFAOYSA-N 0.000 claims 2
- NDGRIVZUQDOJBP-VIFPVBQESA-N 2-[[2-methyl-6-[(3s)-pyrrolidin-3-yl]oxypyrimidin-4-yl]amino]-1,3-thiazole-5-carbonitrile Chemical compound C=1C(O[C@@H]2CNCC2)=NC(C)=NC=1NC1=NC=C(C#N)S1 NDGRIVZUQDOJBP-VIFPVBQESA-N 0.000 claims 2
- BHXHDXIVJVSHQH-UHFFFAOYSA-N 2-[[6-(3-morpholin-4-ylpropylamino)pyrimidin-4-yl]amino]-1,3-thiazole-5-carbonitrile Chemical compound S1C(C#N)=CN=C1NC1=CC(NCCCN2CCOCC2)=NC=N1 BHXHDXIVJVSHQH-UHFFFAOYSA-N 0.000 claims 2
- NIPLEYWULBKSHR-UHFFFAOYSA-N 5-phenyl-n-(6-piperidin-4-yloxypyrimidin-4-yl)-1,3-thiazol-2-amine Chemical compound C1CNCCC1OC1=CC(NC=2SC(=CN=2)C=2C=CC=CC=2)=NC=N1 NIPLEYWULBKSHR-UHFFFAOYSA-N 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 2
- 102100025306 Integrin alpha-IIb Human genes 0.000 claims 2
- 101710149643 Integrin alpha-IIb Proteins 0.000 claims 2
- 206010033266 Ovarian Hyperstimulation Syndrome Diseases 0.000 claims 2
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 claims 2
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 claims 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 claims 2
- 206010064930 age-related macular degeneration Diseases 0.000 claims 2
- 239000005557 antagonist Substances 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 208000030533 eye disease Diseases 0.000 claims 2
- 125000005842 heteroatom Chemical group 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 208000002780 macular degeneration Diseases 0.000 claims 2
- 125000002950 monocyclic group Chemical group 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 230000016087 ovulation Effects 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 238000001959 radiotherapy Methods 0.000 claims 2
- 230000004936 stimulating effect Effects 0.000 claims 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 2
- 230000000451 tissue damage Effects 0.000 claims 2
- 231100000827 tissue damage Toxicity 0.000 claims 2
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 claims 1
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 1
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 claims 1
- AJXHBPDYXACVLJ-UHFFFAOYSA-N 2-[(6-piperidin-4-yloxypyrimidin-4-yl)amino]-1,3-thiazole-5-carbonitrile Chemical compound S1C(C#N)=CN=C1NC1=CC(OC2CCNCC2)=NC=N1 AJXHBPDYXACVLJ-UHFFFAOYSA-N 0.000 claims 1
- OQZMLPYKCSMWCP-UHFFFAOYSA-N 2-[(6-piperidin-4-ylsulfanylpyrimidin-4-yl)amino]-1,3-thiazole-5-carbonitrile Chemical compound S1C(C#N)=CN=C1NC1=CC(SC2CCNCC2)=NC=N1 OQZMLPYKCSMWCP-UHFFFAOYSA-N 0.000 claims 1
- JUCRVOPOJXROMZ-UHFFFAOYSA-N 2-[2-[[6-[(5-cyano-1,3-thiazol-2-yl)amino]-2-methylpyrimidin-4-yl]amino]piperidin-1-yl]-n-propan-2-ylacetamide Chemical compound CC(C)NC(=O)CN1CCCCC1NC1=CC(NC=2SC(=CN=2)C#N)=NC(C)=N1 JUCRVOPOJXROMZ-UHFFFAOYSA-N 0.000 claims 1
- JNWJVIYRMGXYLR-UHFFFAOYSA-N 2-[4-[[6-[(5-cyano-1,3-thiazol-2-yl)amino]-2-methylpyrimidin-4-yl]oxymethyl]piperidin-1-yl]acetic acid Chemical compound C=1C(OCC2CCN(CC(O)=O)CC2)=NC(C)=NC=1NC1=NC=C(C#N)S1 JNWJVIYRMGXYLR-UHFFFAOYSA-N 0.000 claims 1
- UZQYCXNCJRHTFJ-UHFFFAOYSA-N 2-[5-methyl-6-(piperidin-4-ylamino)pyrimidin-4-yl]oxy-1,3-thiazole-5-carbonitrile Chemical compound N1=CN=C(OC=2SC(=CN=2)C#N)C(C)=C1NC1CCNCC1 UZQYCXNCJRHTFJ-UHFFFAOYSA-N 0.000 claims 1
- JJCMGNMUYUTOCB-UHFFFAOYSA-N 2-[[2-methyl-6-(2-morpholin-4-ylethoxy)pyrimidin-4-yl]amino]-1,3-thiazole-5-carbonitrile Chemical compound C=1C(OCCN2CCOCC2)=NC(C)=NC=1NC1=NC=C(C#N)S1 JJCMGNMUYUTOCB-UHFFFAOYSA-N 0.000 claims 1
- WNVVVMNKLMNWAH-UHFFFAOYSA-N 2-[[2-methyl-6-(2-morpholin-4-ylethylamino)pyrimidin-4-yl]amino]-1,3-thiazole-5-carbonitrile Chemical compound C=1C(NC=2SC(=CN=2)C#N)=NC(C)=NC=1NCCN1CCOCC1 WNVVVMNKLMNWAH-UHFFFAOYSA-N 0.000 claims 1
- VGBXWUIRJDXYGD-UHFFFAOYSA-N 2-[[2-methyl-6-(2-morpholin-4-ylethylsulfanyl)pyrimidin-4-yl]amino]-1,3-thiazole-5-carbonitrile Chemical compound C=1C(SCCN2CCOCC2)=NC(C)=NC=1NC1=NC=C(C#N)S1 VGBXWUIRJDXYGD-UHFFFAOYSA-N 0.000 claims 1
- RRGNLSPIERWMSN-UHFFFAOYSA-N 2-[[2-methyl-6-(2-piperidin-1-ylethoxy)pyrimidin-4-yl]amino]-1,3-thiazole-5-carbonitrile Chemical compound C=1C(OCCN2CCCCC2)=NC(C)=NC=1NC1=NC=C(C#N)S1 RRGNLSPIERWMSN-UHFFFAOYSA-N 0.000 claims 1
- ZLPLVZIVZNTCLE-UHFFFAOYSA-N 2-[[2-methyl-6-(3-morpholin-4-ylpropoxy)pyrimidin-4-yl]amino]-1,3-thiazole-5-carbonitrile Chemical compound C=1C(OCCCN2CCOCC2)=NC(C)=NC=1NC1=NC=C(C#N)S1 ZLPLVZIVZNTCLE-UHFFFAOYSA-N 0.000 claims 1
- FNGOZGCBJZSAPH-UHFFFAOYSA-N 2-[[2-methyl-6-(oxan-4-ylamino)pyrimidin-4-yl]amino]-1,3-thiazole-5-carbonitrile Chemical compound C=1C(NC=2SC(=CN=2)C#N)=NC(C)=NC=1NC1CCOCC1 FNGOZGCBJZSAPH-UHFFFAOYSA-N 0.000 claims 1
- VPMQRJXWAPWEEL-UHFFFAOYSA-N 2-[[2-methyl-6-(piperidin-4-ylamino)pyrimidin-4-yl]amino]-1,3-thiazole-5-carbonitrile Chemical compound C=1C(NC=2SC(=CN=2)C#N)=NC(C)=NC=1NC1CCNCC1 VPMQRJXWAPWEEL-UHFFFAOYSA-N 0.000 claims 1
- MJTVIEHXCFQDDI-UHFFFAOYSA-N 2-[[2-methyl-6-(piperidin-4-ylmethylamino)pyrimidin-4-yl]amino]-1,3-thiazole-5-carbonitrile Chemical compound C=1C(NC=2SC(=CN=2)C#N)=NC(C)=NC=1NCC1CCNCC1 MJTVIEHXCFQDDI-UHFFFAOYSA-N 0.000 claims 1
- NDGRIVZUQDOJBP-SECBINFHSA-N 2-[[2-methyl-6-[(3r)-pyrrolidin-3-yl]oxypyrimidin-4-yl]amino]-1,3-thiazole-5-carbonitrile Chemical compound C=1C(O[C@H]2CNCC2)=NC(C)=NC=1NC1=NC=C(C#N)S1 NDGRIVZUQDOJBP-SECBINFHSA-N 0.000 claims 1
- PXYDNYQZIPUIKI-UHFFFAOYSA-N 2-[[6-(1,4-dioxan-2-ylmethylamino)-2-methylpyrimidin-4-yl]amino]-1,3-thiazole-5-carbonitrile Chemical compound C=1C(NC=2SC(=CN=2)C#N)=NC(C)=NC=1NCC1COCCO1 PXYDNYQZIPUIKI-UHFFFAOYSA-N 0.000 claims 1
- QINGBMINRYJAMY-UHFFFAOYSA-N 2-[[6-(3-imidazol-1-ylpropylamino)-2-methylpyrimidin-4-yl]amino]-1,3-thiazole-5-carbonitrile Chemical compound C=1C(NC=2SC(=CN=2)C#N)=NC(C)=NC=1NCCCN1C=CN=C1 QINGBMINRYJAMY-UHFFFAOYSA-N 0.000 claims 1
- KIXFMPQMRGLLJE-UHFFFAOYSA-N 2-[[6-(piperidin-4-ylmethoxy)pyrimidin-4-yl]amino]-1,3-thiazole-5-carbonitrile Chemical compound S1C(C#N)=CN=C1NC1=CC(OCC2CCNCC2)=NC=N1 KIXFMPQMRGLLJE-UHFFFAOYSA-N 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 claims 1
- 102000012936 Angiostatins Human genes 0.000 claims 1
- 108010079709 Angiostatins Proteins 0.000 claims 1
- 108010062540 Chorionic Gonadotropin Proteins 0.000 claims 1
- 102000011022 Chorionic Gonadotropin Human genes 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- HVXBOLULGPECHP-WAYWQWQTSA-N Combretastatin A4 Chemical compound C1=C(O)C(OC)=CC=C1\C=C/C1=CC(OC)=C(OC)C(OC)=C1 HVXBOLULGPECHP-WAYWQWQTSA-N 0.000 claims 1
- 108090000266 Cyclin-dependent kinases Proteins 0.000 claims 1
- 102000003903 Cyclin-dependent kinases Human genes 0.000 claims 1
- 206010012442 Dermatitis contact Diseases 0.000 claims 1
- 201000009273 Endometriosis Diseases 0.000 claims 1
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 claims 1
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 claims 1
- 108700012941 GNRH1 Proteins 0.000 claims 1
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 claims 1
- 102000006992 Interferon-alpha Human genes 0.000 claims 1
- 108010047761 Interferon-alpha Proteins 0.000 claims 1
- 102000013462 Interleukin-12 Human genes 0.000 claims 1
- 108010065805 Interleukin-12 Proteins 0.000 claims 1
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 108010073521 Luteinizing Hormone Proteins 0.000 claims 1
- 102000009151 Luteinizing Hormone Human genes 0.000 claims 1
- 229940124761 MMP inhibitor Drugs 0.000 claims 1
- 208000001344 Macular Edema Diseases 0.000 claims 1
- 206010025415 Macular oedema Diseases 0.000 claims 1
- 206010027202 Meningitis bacterial Diseases 0.000 claims 1
- 108010057021 Menotropins Proteins 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- 108010016731 PPAR gamma Proteins 0.000 claims 1
- 229930012538 Paclitaxel Natural products 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 102100038825 Peroxisome proliferator-activated receptor gamma Human genes 0.000 claims 1
- 229940080774 Peroxisome proliferator-activated receptor gamma agonist Drugs 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 208000007135 Retinal Neovascularization Diseases 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- UIRKNQLZZXALBI-MSVGPLKSSA-N Squalamine Chemical compound C([C@@H]1C[C@H]2O)[C@@H](NCCCNCCCCN)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CC[C@H](C(C)C)OS(O)(=O)=O)[C@@]2(C)CC1 UIRKNQLZZXALBI-MSVGPLKSSA-N 0.000 claims 1
- UIRKNQLZZXALBI-UHFFFAOYSA-N Squalamine Natural products OC1CC2CC(NCCCNCCCCN)CCC2(C)C2C1C1CCC(C(C)CCC(C(C)C)OS(O)(=O)=O)C1(C)CC2 UIRKNQLZZXALBI-UHFFFAOYSA-N 0.000 claims 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 125000002947 alkylene group Chemical group 0.000 claims 1
- 125000005275 alkylenearyl group Chemical group 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 230000003110 anti-inflammatory effect Effects 0.000 claims 1
- 239000002220 antihypertensive agent Substances 0.000 claims 1
- FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 claims 1
- 201000009904 bacterial meningitis Diseases 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 201000008275 breast carcinoma Diseases 0.000 claims 1
- OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical group C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 claims 1
- 229960002802 bromocriptine Drugs 0.000 claims 1
- 230000002490 cerebral effect Effects 0.000 claims 1
- 229940015047 chorionic gonadotropin Drugs 0.000 claims 1
- GKIRPKYJQBWNGO-OCEACIFDSA-N clomifene Chemical compound C1=CC(OCCN(CC)CC)=CC=C1C(\C=1C=CC=CC=1)=C(\Cl)C1=CC=CC=C1 GKIRPKYJQBWNGO-OCEACIFDSA-N 0.000 claims 1
- 229960003608 clomifene Drugs 0.000 claims 1
- 229960005537 combretastatin A-4 Drugs 0.000 claims 1
- HVXBOLULGPECHP-UHFFFAOYSA-N combretastatin A4 Natural products C1=C(O)C(OC)=CC=C1C=CC1=CC(OC)=C(OC)C(OC)=C1 HVXBOLULGPECHP-UHFFFAOYSA-N 0.000 claims 1
- 208000010247 contact dermatitis Diseases 0.000 claims 1
- 229940111134 coxibs Drugs 0.000 claims 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- 230000009977 dual effect Effects 0.000 claims 1
- 229940125436 dual inhibitor Drugs 0.000 claims 1
- 210000000981 epithelium Anatomy 0.000 claims 1
- 239000002834 estrogen receptor modulator Substances 0.000 claims 1
- RWTNPBWLLIMQHL-UHFFFAOYSA-N fexofenadine Chemical compound C1=CC(C(C)(C(O)=O)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 RWTNPBWLLIMQHL-UHFFFAOYSA-N 0.000 claims 1
- 210000002950 fibroblast Anatomy 0.000 claims 1
- 229940028334 follicle stimulating hormone Drugs 0.000 claims 1
- 238000001415 gene therapy Methods 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 102000006495 integrins Human genes 0.000 claims 1
- 108010044426 integrins Proteins 0.000 claims 1
- 229940117681 interleukin-12 Drugs 0.000 claims 1
- 230000000302 ischemic effect Effects 0.000 claims 1
- 210000000867 larynx Anatomy 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 201000005249 lung adenocarcinoma Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 229940040129 luteinizing hormone Drugs 0.000 claims 1
- 210000004324 lymphatic system Anatomy 0.000 claims 1
- 201000010230 macular retinal edema Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- YSRXZZKWZJOLNZ-UHFFFAOYSA-N n-(2-methyl-6-piperidin-4-yloxypyrimidin-4-yl)-5-phenyl-1,3-thiazol-2-amine Chemical compound C=1C(OC2CCNCC2)=NC(C)=NC=1NC(S1)=NC=C1C1=CC=CC=C1 YSRXZZKWZJOLNZ-UHFFFAOYSA-N 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 201000008968 osteosarcoma Diseases 0.000 claims 1
- 229960001592 paclitaxel Drugs 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 230000007170 pathology Effects 0.000 claims 1
- 229940043138 pentosan polysulfate Drugs 0.000 claims 1
- 238000002428 photodynamic therapy Methods 0.000 claims 1
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 claims 1
- 201000011461 pre-eclampsia Diseases 0.000 claims 1
- 239000002599 prostaglandin synthase inhibitor Substances 0.000 claims 1
- 229960004622 raloxifene Drugs 0.000 claims 1
- GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 claims 1
- 201000006845 reticulosarcoma Diseases 0.000 claims 1
- 208000029922 reticulum cell sarcoma Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 208000007442 rickets Diseases 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
- 229950001248 squalamine Drugs 0.000 claims 1
- 230000003637 steroidlike Effects 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
- 229960001603 tamoxifen Drugs 0.000 claims 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 1
- GGHSPLOGDCKWKX-UHFFFAOYSA-N tert-butyl 2-[[6-[(5-cyano-1,3-thiazol-2-yl)amino]-2-methylpyrimidin-4-yl]oxymethyl]morpholine-4-carboxylate Chemical compound C=1C(OCC2OCCN(C2)C(=O)OC(C)(C)C)=NC(C)=NC=1NC1=NC=C(C#N)S1 GGHSPLOGDCKWKX-UHFFFAOYSA-N 0.000 claims 1
- HLFUHRZVPXEVOJ-UHFFFAOYSA-N tert-butyl 4-[[6-[(5-phenyl-1,3-thiazol-2-yl)amino]pyrimidin-4-yl]oxymethyl]piperidine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC1COC1=CC(NC=2SC(=CN=2)C=2C=CC=CC=2)=NC=N1 HLFUHRZVPXEVOJ-UHFFFAOYSA-N 0.000 claims 1
- 229960003433 thalidomide Drugs 0.000 claims 1
- COKMIXFXJJXBQG-NRFANRHFSA-N tirofiban Chemical group C1=CC(C[C@H](NS(=O)(=O)CCCC)C(O)=O)=CC=C1OCCCCC1CCNCC1 COKMIXFXJJXBQG-NRFANRHFSA-N 0.000 claims 1
- 229960003425 tirofiban Drugs 0.000 claims 1
- 229960000575 trastuzumab Drugs 0.000 claims 1
- 208000027930 type IV hypersensitivity disease Diseases 0.000 claims 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims 1
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US42231302P | 2002-10-30 | 2002-10-30 | |
| PCT/US2003/034100 WO2004041164A2 (fr) | 2002-10-30 | 2003-10-24 | Inhibiteurs de kinase |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006507302A JP2006507302A (ja) | 2006-03-02 |
| JP2006507302A5 true JP2006507302A5 (fr) | 2006-08-03 |
Family
ID=32312490
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004550143A Withdrawn JP2006507302A (ja) | 2002-10-30 | 2003-10-24 | キナーゼ阻害剤 |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1558609A4 (fr) |
| JP (1) | JP2006507302A (fr) |
| AU (1) | AU2003285007A1 (fr) |
| CA (1) | CA2503715A1 (fr) |
| WO (1) | WO2004041164A2 (fr) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA05007485A (es) | 2003-01-14 | 2006-01-30 | Arena Pharm Inc | Derivados de arilo y heteroarilo 1,2,3-trisubstituidos como moduladores del metabolismo y la profilaxis y tratamiento de trastornos relacionados con ello tales como diabetes e hiperglicemia. |
| US8168568B1 (en) | 2003-03-10 | 2012-05-01 | The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Combinatorial therapy for protein signaling diseases |
| AR045047A1 (es) * | 2003-07-11 | 2005-10-12 | Arena Pharm Inc | Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos |
| DK1756084T3 (da) * | 2004-06-04 | 2009-03-23 | Arena Pharm Inc | Substituerede aryl- og heteroarylderivater som modulatorer af metabolisme og forebyggelse og behandling af forstyrrelser beslægtet dermed |
| EP1835913A2 (fr) | 2004-12-06 | 2007-09-26 | Avigen, Inc. | Jbudilast pour le traitement de la douleur neuropathique et des syndromes associés |
| MY148521A (en) * | 2005-01-10 | 2013-04-30 | Arena Pharm Inc | Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto |
| RU2416410C2 (ru) | 2005-04-29 | 2011-04-20 | Ферринг Интернэшнл Сентер С.А. | Лечение или профилактика синдрома гиперстимуляции яичников (ohss) с использованием агониста дофамина |
| JP2008542219A (ja) * | 2005-05-25 | 2008-11-27 | インゲニウム ファーマシューティカルズ ジーエムビーエイチ | 疼痛処置法 |
| CA2634442A1 (fr) * | 2005-12-22 | 2007-07-05 | Icagen, Inc. | Antagonistes du canal calcique |
| ES2378704T3 (es) * | 2006-01-27 | 2012-04-17 | Array Biopharma, Inc. | Activadores de la glucocinasa |
| US20080051380A1 (en) | 2006-08-25 | 2008-02-28 | Auerbach Alan H | Methods and compositions for treating cancer |
| ES2593486T3 (es) | 2007-04-18 | 2016-12-09 | Pfizer Products Inc. | Derivados de sulfonil amida para el tratamiento del crecimiento celular anómalo |
| EP2137166B1 (fr) | 2007-04-24 | 2012-05-30 | Ingenium Pharmaceuticals GmbH | Dérivés d'aminopyrimidines 4,6 disubstitués comme inhibiteurs de protéine kinase |
| ES2393824T3 (es) | 2007-09-21 | 2012-12-28 | Array Biopharma, Inc. | Derivados de piridin-2-il-amino-1,2,4-tiadiazol como activadores de glucoquinasa para el tratamiento de diabetes mellitus |
| GB0811955D0 (en) | 2008-06-30 | 2008-07-30 | Pci Biotech As | Method |
| WO2010059384A1 (fr) * | 2008-10-30 | 2010-05-27 | Janssen Pharmaceutica Nv | Procédé de préparation de dérivés de pyridine tri-substituée et de pyrimidine tri-substituée utiles comme agonistes du récepteur du peptide insulinotrope glucose-dépendant |
| EP2571867B1 (fr) | 2010-05-21 | 2015-11-04 | Noviga Research AB | Nouveaux dérivés de pyrimidine |
| BR112013008100A2 (pt) | 2010-09-22 | 2016-08-09 | Arena Pharm Inc | "moduladores do receptor de gpr19 e o tratamento de distúrbios relacionados a eles." |
| US9006241B2 (en) | 2011-03-24 | 2015-04-14 | Noviga Research Ab | Pyrimidine derivatives |
| EP2702043A1 (fr) * | 2011-04-29 | 2014-03-05 | Exelixis, Inc. | Inhibiteurs de la forme inductible de la 6-phosphofructose-2-kinase |
| US11007175B2 (en) | 2015-01-06 | 2021-05-18 | Arena Pharmaceuticals, Inc. | Methods of treating conditions related to the S1P1 receptor |
| CN108349891B (zh) | 2015-06-22 | 2022-04-05 | 艾尼纳制药公司 | 用于s1p1受体相关病症的化合物的结晶l-精氨酸盐 |
| TWI620748B (zh) * | 2016-02-05 | 2018-04-11 | National Health Research Institutes | 氨基噻唑化合物及其用途 |
| US20180028521A1 (en) | 2016-07-29 | 2018-02-01 | Janssen Pharmaceutica Nv | Methods of Treating Prostate Cancer |
| MX2019009841A (es) | 2017-02-16 | 2020-01-30 | Arena Pharm Inc | Compuestos y metodos para el tratamiento de la colangitis biliar primaria. |
| TWI667236B (zh) | 2017-06-13 | 2019-08-01 | 財團法人國家衛生研究院 | 作為蛋白激酶抑制劑的胺基噻唑化合物 |
| EP3643713A1 (fr) * | 2018-10-23 | 2020-04-29 | iOmx Therapeutics AG | Inhibiteurs de kinase hétérocycliques et leurs utilisations |
| CN111116575B (zh) * | 2019-12-18 | 2021-06-15 | 浙江工业大学 | 一种5-氟-2,4-嘧啶二胺类化合物及其制备与应用 |
| CN111388656B (zh) * | 2020-04-17 | 2021-01-15 | 广州医科大学附属第三医院（广州重症孕产妇救治中心、广州柔济医院） | Kallistatin蛋白在制备防治OHSS的药物中的应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2312860C2 (ru) * | 1999-04-15 | 2007-12-20 | Бристол-Маерс Сквибб Компани | Циклические ингибиторы протеинтирозинкиназ |
| US20020137755A1 (en) * | 2000-12-04 | 2002-09-26 | Bilodeau Mark T. | Tyrosine kinase inhibitors |
| DK1347971T3 (da) * | 2000-12-21 | 2006-05-15 | Bristol Myers Squibb Co | Thiazolylinhibitorer af tyrosinkinaser fra Tec-familien |
-
2003
- 2003-10-24 AU AU2003285007A patent/AU2003285007A1/en not_active Abandoned
- 2003-10-24 EP EP03779322A patent/EP1558609A4/fr not_active Withdrawn
- 2003-10-24 CA CA002503715A patent/CA2503715A1/fr not_active Abandoned
- 2003-10-24 WO PCT/US2003/034100 patent/WO2004041164A2/fr active Application Filing
- 2003-10-24 JP JP2004550143A patent/JP2006507302A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006507302A5 (fr) | ||
| AU2015317327B9 (en) | Pyridinyl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors | |
| JP5261575B2 (ja) | 化学化合物 | |
| ES2255621T3 (es) | Inhibidores de tirosina quinasa. | |
| DK2164843T3 (en) | pyridazinone | |
| CA3002610C (fr) | Utilisation de derives d'indole n-substitues comme modulateurs des recepteurs des pge2 | |
| US20190345138A1 (en) | Heterocyclic amides as kinase inhibitors | |
| JP2011526616A5 (fr) | ||
| JP2009541311A5 (fr) | ||
| JP2013544256A5 (fr) | ||
| JP5538528B2 (ja) | 新規なｇｐｒ１１９アゴニスト | |
| CN101605540A (zh) | 使用mek抑制剂的方法 | |
| US20130324551A1 (en) | Thiazolylphenyl-benzenesulfonamido derivatives as kinase inhibitors | |
| JP2014528450A5 (fr) | ||
| JP2017525757A5 (fr) | ||
| CA2677481A1 (fr) | Composes a base de triazole modulant l'activite de hsp90 | |
| MX2009001427A (es) | Derivados de 2-(heterociclilbencil)-piridazinona. | |
| CN102171214A (zh) | 聚(adp-核糖)聚合酶(parp)的二氢吡啶并酞嗪酮抑制剂 | |
| MXPA02002559A (es) | Inhibidores de tirosina cinasa. | |
| JP2019505595A5 (fr) | ||
| RU2018138047A (ru) | Гетероциклические вещества - агонисты gpr119 | |
| JP5922128B2 (ja) | ヒスタミンｈ４受容体リガンドとしてのベンザゾール誘導体 | |
| JP2010511628A5 (fr) | ||
| JP2012531456A5 (fr) | ||
| RU2011122942A (ru) | Новые ингибиторы киназ |